Ropes & Gray Represents EQRx in Turning Point Therapeutics Collaboration on Combination Drug for Non-Small Cell Lung Cancer
Ropes & Gray advised EQRx in a clinical collaboration with oncology company Turning Point Therapeutics to evaluate Turning Point’s drug elzovantinib and EQRx’s drug aumolertinib for a certain type of advanced non-small cell lung cancer. The transaction was announced on October 13.
Under the terms of the agreement, Turning Point will sponsor and conduct a Phase 1b/2 clinical trial expected to begin in 2022 to evaluate the safety, tolerability and preliminary efficacy of the combination regimen.
The Ropes & Gray team was led by life sciences partner Abigail Gregor and life sciences associate Amanda White (both of Boston).